Managing pain—especially after surgery or an injury—can be challenging, and many people worry about the risks of opioid medications. This concern is even greater for older adults, who may be more vulnerable to side effects and complications. Now, there’s a new option: Journavx, a non-opioid pain medication recently approved by the FDA.

What Is Journavx?

Journavx (suzetrigine) is a newly approved pain medication that works differently than traditional opioids. It belongs to a new class of pain medicine, the first of its kind in more than 20 years.

• What it does: Treats moderate to severe acute pain, such as pain after surgery or injury.
• How it works: Targets sodium channels in the peripheral nervous system, blocking pain signals before they reach the brain.
• Why it’s different: Unlike opioids, it does not carry the risk of addiction or overdose.

How It Benefits Seniors

For older adults, pain management can be complex due to potential side effects and interactions. Journavx offers several benefits for seniors:

• Lower Risk of Cognitive Impairment: Opioids can cause confusion, drowsiness, and increase the risk of falls. Research suggests that opioid use may contribute to cognitive impairment, making Journavx a potential alternative.
• No Addiction Potential: Unlike opioids, which can lead to dependency, Journavx eliminates this risk.
• Fewer Drug Interactions: It may reduce the risk of dangerous interactions, a common concern for individuals on multiple medications.
• Improved Recovery: Effective pain management without sedation or dizziness helps older adults stay active and engaged in their recovery process.

Why This Approval Matters

Many pain medications available today are opioids, which can be effective but come with serious risks, including addiction. Key statistics include:

• Over 80 million Americans seek pain relief each year
• 40 million Americans receive opioids for pain
• In 2023, more than 81,000 people died from opioid-related overdoses in the U.S.

While opioids are effective, their long-term use can lead to addiction. If not managed properly, pain can disrupt daily life and even become chronic, highlighting the need for safer, effective alternatives. The approval of Journavx provides a new option for managing pain without these risks. FDA officials see this as a major step in providing a safer option.

How Effective Is Journavx?

Clinical trials showed that Journavx significantly reduced pain compared to a placebo. However, it did not outperform a commonly used opioid-acetaminophen combination pill. Its key advantage is its safer side effect profile, especially the lack of addiction risk.

Cost and Insurance Coverage

Journavx costs $15.50 per pill, which is more expensive than many opioid alternatives. While insurance coverage details are still being finalized, patient support programs are available to help with costs. It’s advisable to check with your insurance provider for coverage options.

What This Means for You or Your Loved One

If you or a loved one needs short-term pain management, Journavx could be a safer alternative to opioids. Talk with your healthcare provider about whether this new medication is right for your situation.

At American Baptist Homes of the Midwest and your ABHM community, we prioritize the well-being of our residents by staying informed about advancements in healthcare that support safer, more effective recovery. As new options like Journavx become available, we remain committed to helping families make informed decisions about care.